Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report | Zendy

Nakahara Ryosuke | Zendy; Sumimoto Takahiro | Zendy; Ogata Masao | Zendy; Sato Yuhki | Zendy; Itoh Hiroki | Zendy

Open Access

Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report

Author(s) -

Nakahara Ryosuke,

Sumimoto Takahiro,

Ogata Masao,

Sato Yuhki,

Itoh Hiroki

Publication year - 2019

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.2191

Subject(s) - nilotinib , medicine , myeloid leukemia , therapeutic drug monitoring , dosing , drug , tyrosine kinase inhibitor , pharmacology , tyrosine kinase , bosutinib , oncology , intensive care medicine , imatinib , cancer , receptor

Fixed dosage regimen is currently the standard therapy with tyrosine kinase inhibitors (TKI). This case report demonstrates successful determination of nilotinib dosage by therapeutic drug monitoring (TDM) in a patient with chronic myeloid leukemia (CML). TDM may provide useful marker for individualized dosing of TKI for the treatment of CML.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research